1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

Areteia Therapeutics

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2022

Location

Chapel Hill NC US

Primary Industry

Biotechnology

About

Based in North Carolina, US, Areteia Therapeutics, Inc. was created by Population Health Partners and Knopp Biosciences in 2022 and is a biopharmaceutical company in its clinical stage that develops an oral drug for eosinophilic asthma. In July 2022, Areteia Therapeutics, Inc. raised USD 350 million in series A funding led by new investor Bain Capital Life Sciences, with participation from other new investors Access Industries, ARCH Venture Partners, etc. As of July 2022, Jorge Bartolome is the CEO of the company. The company is conducting clinical trials of its oral medicine dexpramipexole, which has the potential to target eosinophils in the blood and prevent them from traveling through the blood to the lungs of people suffering from eosinophilic asthma and reducing their effect on the lungs before they cause further damage. The company intends to use the July 2022 funding to promote its advanced dexpramipexole through Phase 3 clinical trials, secure commercial supply, and pursue potential next-generation medicines.
Current Investors
ARCH Venture Partners, Access Industries, GV

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.areteiatx.com
Company Stage
Series A
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.